Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, ...

BridgeBio Pharma has declined to participate in the National Advertising Division’s (NAD’s) investigation into complaints made by Pfizer, leading the self-regulatory body to refer the case to federal ...

Sept 3 (Reuters) - Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab on Wednesday defended their COVID-19 vaccines as having saved millions of lives worldwide, in separate responses to ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing ...